The Use of Tinfliximab in Cutaneous Sarcoidosis

August 2003 | Volume 2 | Issue 4 | Case Reports | 413 | Copyright © August 2003

Jon H. Meyerle, MD and Andrew Shoor, MD

Abstract
Infliximab, a chimeric (humanized mouse) monoclonal antibody which specifically inhibits TNF-?, has recently shown efficacy in the treatment of refractory sarcoidosis1,2. The manifestations of sarcoidosis are diverse; however, the long-term effects on the lungs are often the most life-threatening. We describe a patient with sarcoidosis who experienced the complete resolution of her cutaneous disease and stabilization of her pulmonary symptoms after initiation of infliximab.